Study Investigates Needs of Amyloidosis and Immunoglobulin Deposition Disease Patients During COVID-19
source: pixabay.com

Study Investigates Needs of Amyloidosis and Immunoglobulin Deposition Disease Patients During COVID-19

Throughout the COVID-19 pandemic, researchers have been dedicated to understanding which individuals are most at risk for severe disease. They've found that those who are immunocompromised and have certain cancers…

Continue Reading Study Investigates Needs of Amyloidosis and Immunoglobulin Deposition Disease Patients During COVID-19
Last Patient Treated in CARES10 Trial for Primary Immunodeficiency (PI)
[Source: pixabay.com]

Last Patient Treated in CARES10 Trial for Primary Immunodeficiency (PI)

According to a recent press release, biopharmaceutical company Kedrion Biopharma ("Kedrion") achieved an important milestone in its Phase 3 CARES10 trial: the last treated patient. During the CARES10 trial, researchers evaluated…

Continue Reading Last Patient Treated in CARES10 Trial for Primary Immunodeficiency (PI)
What is the Recommended CAEL-101 Dose for AL Amyloidosis?
Source: https://pixabay.com/en/hospital-infusion-drip-antibiotic-834152/

What is the Recommended CAEL-101 Dose for AL Amyloidosis?

In early December 2020, many descended upon the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to discuss insights in the field of hematology. During the Meeting, researchers…

Continue Reading What is the Recommended CAEL-101 Dose for AL Amyloidosis?
Impressive Results for Cilta-Cel to Treat Patients With Relapsed/Refractory Multiple Myeloma
qimono / Pixabay

Impressive Results for Cilta-Cel to Treat Patients With Relapsed/Refractory Multiple Myeloma

According to a recent report in Cancer Network, the results from CARTITUDE-1 were well received. CARTITUDE-1 is a phase 1b/2 clinical trial of the CAR T-cell treatment, Cilta-Cel, for the…

Continue Reading Impressive Results for Cilta-Cel to Treat Patients With Relapsed/Refractory Multiple Myeloma

Investigative Therapy to Treat Underlying Cause of Systemic Mastocytosis is Under FDA Review

Blueprint Medicines Corporation has just announced that they have submitted a supplemental New Drug Application (NDA) to the FDA. This application is for a therapy called AYVAKIT, which was developed…

Continue Reading Investigative Therapy to Treat Underlying Cause of Systemic Mastocytosis is Under FDA Review
Study: What is the Role of Fibrocytes and Endothelial Progenitor Cells in Lung Sarcoidosis?
source: pixabay.com

Study: What is the Role of Fibrocytes and Endothelial Progenitor Cells in Lung Sarcoidosis?

A study published in BMC Pulmonary Medicine focuses on the role of endothelial progenitor cells and fibrocytes in lung sarcoidosis. They specifically investigated how these cells, along with CD34 + cells, spurred…

Continue Reading Study: What is the Role of Fibrocytes and Endothelial Progenitor Cells in Lung Sarcoidosis?